These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 17983259)
21. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Arber N; Lieberman D; Wang TC; Zhang R; Sands GH; Bertagnolli MM; Hawk ET; Eagle C; Coindreau J; Zauber A; Lanas A; Levin B Clin Ther; 2012 Mar; 34(3):569-79. PubMed ID: 22386831 [TBL] [Abstract][Full Text] [Related]
24. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Hasegawa M; Horiki N; Tanaka K; Wakabayashi H; Tano S; Katsurahara M; Uchida A; Takei Y; Sudo A Mod Rheumatol; 2013 Nov; 23(6):1172-8. PubMed ID: 23306427 [TBL] [Abstract][Full Text] [Related]
25. Augmented chondroprotective effect of coadministration of celecoxib and rebamipide in the monosodium iodoacetate rat model of osteoarthritis. Moon SJ; Park JS; Jeong JH; Yang EJ; Park MK; Kim EK; Park SH; Kim HY; Cho ML; Min JK Arch Pharm Res; 2013 Jan; 36(1):116-24. PubMed ID: 23338062 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. Kellner HL; Li C; Essex MN Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870 [TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain. Moberly JB; Xu J; Desjardins PJ; Daniels SE; Bandy DP; Lawson JE; Link AJ; Truitt KE Clin Ther; 2007 Mar; 29(3):399-412. PubMed ID: 17577461 [TBL] [Abstract][Full Text] [Related]
28. Are rofecoxib and celecoxib safer NSAIDS? Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599 [TBL] [Abstract][Full Text] [Related]
29. Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis. Davies NM; Gudde TW; de Leeuw MA Expert Opin Pharmacother; 2001 Jan; 2(1):139-52. PubMed ID: 11336575 [TBL] [Abstract][Full Text] [Related]
30. Celecoxib for the prevention of sporadic colorectal adenomas. Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET; N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400 [TBL] [Abstract][Full Text] [Related]
31. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint. Park YG; Ha CW; Han CD; Bin SI; Kim HC; Jung YB; Lim HC J Ethnopharmacol; 2013 Oct; 149(3):816-24. PubMed ID: 23954277 [TBL] [Abstract][Full Text] [Related]
32. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469 [TBL] [Abstract][Full Text] [Related]
34. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563 [TBL] [Abstract][Full Text] [Related]
35. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Matheson AJ; Figgitt DP Drugs; 2001; 61(6):833-65. PubMed ID: 11398914 [TBL] [Abstract][Full Text] [Related]
36. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Cryer B; Li C; Simon LS; Singh G; Stillman MJ; Berger MF Am J Gastroenterol; 2013 Mar; 108(3):392-400. PubMed ID: 23399552 [TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Spiegel BM; Targownik L; Dulai GS; Gralnek IM Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551 [TBL] [Abstract][Full Text] [Related]
38. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817 [TBL] [Abstract][Full Text] [Related]
39. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Goldenberg MM Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. Schumacher HR; Berger MF; Li-Yu J; Perez-Ruiz F; Burgos-Vargas R; Li C J Rheumatol; 2012 Sep; 39(9):1859-66. PubMed ID: 22859357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]